Interim Report – RIAS A/S
Interim report – RIAS A/SAttachment2021 08 Interim Report RIAS AS
Day: August 25, 2021
SalMar aquires 45% ownership in Refsnes Laks AS
Written by Customer Service on . Posted in Public Companies.
SalMar has today, 25.08.2021, entered into an agreement to acquire 45% ownership in Refsnes Laks AS through a combination of share purchase and private placement. Refsnes Laks AS currently has four licenses for production of Atlantic salmon and a time limited viewing license in Central Norway, in total 3,932 tonnes MAB. The purchase price for the transaction is NOK 665 million.
Chairman of the board of Refsnes Laks, Ivar Refsnes emphasizes that for many years a close and value-creating collaboration has been developed between SalMar and Refsnes. This applies to production, processing and sales in an international market. SalMar’s acquisition of a significant ownership interest in the company is a natural continuation of this collaboration. It will strengthen the financial basis for the company with its base in Åfjord municipality....
Kering – Launch of share repurchase program
Written by Customer Service on . Posted in Public Companies.
PRESS RELEASE08.25.2021LAUNCH OF SHARE REPURCHASE PROGRAM
Kering announces its intention to repurchase up to 2.0% of its share capital over a 24-month period, pursuant to the share repurchase authorization granted by the General Shareholders’ Meeting held on July 6, 2021, provided that this authorization could evolve at the next General Shareholders’ Meeting due to be held in 2022.
Kering reserves the right to interrupt this program at any time, according to market conditions or to the implementation of its investment strategy.
The shares acquired under this program are to be cancelled, except for those which could be allocated to free share grant programs to some employees.
In this context, Kering has signed a share buyback agreement with an investment service provider.
Under this agreement, a first tranche covering a maximum...
Sydbank’s Interim Report – First Half 2021
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Company Announcement No 12/202125 August 2021
Sydbank’s Interim Report – First Half 2021
Earnings up by 20%
1H 2021 – highlightsProfit of DKK 645m equals a return on equity of 10.4% p.a. after tax.
Core income of DKK 2,193m is 20% higher compared to the same period in 2020.
Costs (core earnings) are 16% higher compared to the same period in 2020 and constitute DKK 1,647m.
Impairment charges for loans and advances represent an income of DKK 206m compared with an expense of DKK 42m in the same period in 2020.
Bank loans and advances constitute DKK 61.4bn – an increase of DKK 1.2bn in 1H 2021.
Total credit intermediation amounts to DKK 168.9bn – an increase of DKK 3.3bn in 1H 2021.
The CET1 ratio has declined by 1.1 percentage points compared to year-end 2020 and constitutes 17.7% excluding profit for the period.We are undertaking a...
Hip Resurfacing Implants Market Report 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast Analysis
Written by Customer Service on . Posted in Mergers And Acquisitions.
Top Players Covered in the Hip Resurfacing Implants Market Research Report are Corentec Co., Ltd., Surgival, B. Braun Melsungen AG, Zimmer Biomet, Conformis, DePuy Synthes, GROUP FH ORTHO communication, Evolutis, Waldemar LINK GmbH & Co. KG, Corin and other key market players
Pune, India, Aug. 25, 2021 (GLOBE NEWSWIRE) — Increasing geriatric population worldwide is expected to drive the global hip resurfacing implants market growth in the foreseeable future. According to the World Population Prospects 2019 report released by the United Nations Population Division, approximately 16% of the world’s population will be over the age of 65 by 2050. In 2018 itself persons at and above 65 years of age outnumbered the number of children in the world and by 2050, people above the age of 80 will reach 426 million.
Aged people typically...
Bavarian Nordic Announces First Half 2021 Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
COPENHAGEN, Denmark, August 25, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2021 and releases its financial calendar for 2022.
Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We are very pleased to confirm the successful execution of our commercial strategy with nearly 30 Rabipur/RabAvert and Encepur markets now transferred to Bavarian Nordic. Our objective during this transition was to stop the historical market share losses before the acquisition of these products, start gaining more ground and increase the awareness of Bavarian Nordic among health care professionals and we are pleased that we today can tick all these boxes, despite that the markets are still impacted by COVID-19. Both the rabies and TBE markets are still...
Interim financial report for 1 January – 30 June 2021 for FirstFarms A/S
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
CEO Anders H. NørgaardCEO Anders H. NørgaardHigh prices on crops and upward adjustment
FirstFarms A/S has in the first half year of 2021 realised the highest prices on crops in history but has also experienced significantly lower pig prices compared to first half year 2020. As FirstFarms is not dependent on individual branches of operation, the company can still present a satisfactory result for first half year of 2021 and adjust the expectations upwards.
The Board of Directors and Management of FirstFarms A/S have today reviewed and adopted the un-audited interim financial accounts for the period 1 January – 30 June 2021.
FirstFarms has in the accounting period realised:A turnover of 143 mDKK
An EBITDA of 57 mDKK
An EBIT of 36 mDKK
A pre-tax result of 25 mDKKThe high crop prices have had a knock-on effect on the sale...
Company Announcement 13/2021
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
August 25, 2021
NORDIC SHIPHOLDING A/SCompany Announcement: 13/2021
Published via NASDAQ OMX on August 25, 2021H1 Result 2021SummaryThe comparison figures for the period ended 30 June 2020 are stated in parenthesis.
The Group performed poorly in the first six months of this year as the Time Charter Equivalent (“TCE”) rates were largely depressed due to low tonnage demand caused by the COVID-19 pandemic coupled with excessive tonnage in the market. As a result, the average daily TCE rate earned in H1 2021 by the vessels was 58% lower than the average daily TCE rate earned in H1 2020.
For the 6 months ended 30 June 2021, the Group incurred a loss after tax of USD 6.0 million (including one-off impairment losses totalling USD 4.8 million on the vessels), compared to a profit after tax of USD 5.7 million (including one-off impairment...
LHV Group finalises investment to acquire a share in Bank North
Written by Customer Service on . Posted in Public Companies.
AS LHV Group finalised an investment of £4.455 million in Bank North (previously B-North) and acquired a 9.9% share in the company after Bank North closed a successful ‘Series A’ funding round and was granted its banking licence by the UK Prudential Regulatory Authority (Authorised with Restrictions – ’AWR’).
In addition to AS LHV Group also pension funds managed by AS LHV Varahaldus invested in Bank North. The other participants in the ‘Series A’ funding round included the likes of Skipton Building Society, Channel 4 Ventures and the Greater Manchester Combined Authority. The round will support Bank North in further developing its technology as well as delivering operating capital to kick off its lending activities.
LHV Group’s investment size of £4.455 million is funded from core tier 1 capital. In the short time frame the investment...
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
Written by Customer Service on . Posted in Public Companies.
Validation initiates formal evaluation of application which started on August 19, 2021; decision expected mid-2022
If approved, efgartigimod will be the first-and-only approved FcRn antagonist in Europe
Regulatory reviews of efgartigimod for generalized myasthenia gravis currently underway in the U.S., Japan and EuropeBreda, the Netherlands – August 25, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it has submitted, and the European Medicines Agency (EMA) has validated, the marketing authorization application (MAA) for the Company’s investigational FcRn antagonist, efgartigimod, for the treatment of generalized myasthenia gravis (gMG). Validation of the MAA confirms that the application...
